In vitro diagnostics (IVD) is a method used for detection and identification of diseases in an artificial environment using samples such as blood, urine, stool, tissues and other body fluids, which are derived from the human body. IVD includes several techniques such as immunodiagnostic, infectious diseases testing, blood testing, clinical chemistry, molecular diagnosis and other such techniques. Considerable increase in the number of chronic and infectious diseases, growing awareness towards healthcare solutions and technological advancements in healthcare industry encouraged doctors and researchers to shift their focus from traditional diagnostic methods to personalized medicines.
The overall revenue of the Asia Pacific IVD market accounted for about $12.9 billion in 2015, and is estimated to reach $19.0 billion by 2022, registering a CAGR of 5.6% over the forecast period. The increased application of personalized medicines and widespread knowledge of rare diseases are boosting the growth of Asia Pacific IVD market. Moreover, growing need of IVD testing owing to increasing incidences of chronic and infectious diseases and growing geriatric population prone to immunological disorders drives the market growth. The Asia Pacific IVD market has evolved over the years with the launch of several innovative techniques used across multiple therapeutic areas. However, stringent regulatory policies and reimbursements issues in few countries limit the growth of this market. The rising demand for technologically advanced diagnostic devices, rise in GDP and per capita income and rise in disposable incomes facilitate a huge potential for the Asia Pacific IVD market in the Asia-Pacific region. Similarly, the development of a new range of condition-specific markers and tests along with the advancement in genomics and proteomics are creating new opportunities in emerging economies.
The Asia-Pacific IVD market is segmented based on product type, technique, indications, end user and country. Based on technique, the market is segmented into immunodiagnostics, blood testing, molecular diagnostics, tissue diagnostics, clinical chemistry and other clinical technique. Immunodiagnostic is the highest revenue-generating segment in the overall IVD techniques market. However, the blood testing is the fastest growing technique in the overall IVD techniques market due to its ability to accurately detect the primary cause of the disease.
Based on product type, the market is segmented into instruments, reagents, services & software. Reagents held the highest market share in the Asia Pacific IVD market followed by rapidly growing instrument segment. Reagents are largely used in various equipment and play a key role in the overall diagnosis process. The application segment is categorized into infectious diseases, cancer, cardiac diseases, immune system diseases, nephrological diseases, gastrointestinal diseases, and others. Infectious diseases segment was the highest revenue-generating segment in 2015 and would continue to maintain its position throughout the forecast period, due to the rise in incidences of infectious diseases such as HIV/AIDS, Chlamydia and Hepatitis.
Hospitals and laboratories, academics & medical schools, point-of-care testing and others form the end users segment in the Asia-Pacific IVD market. Stand-alone laboratories generate the highest revenue, followed by hospitals. A significant rise in the number of hospitals and laboratories across the Asia-Pacific region along with increased awareness about developments in healthcare largely contribute to the growth of these segment.
Based on country, the Asia-Pacific IVD market is segmented into India, China, Japan, Australia, and other Asia-Pacific countries. Japan held the dominant share, around 35.3% in 2015 in the Asia-Pacific IVD market, owing to the high demand for testing in outpatient clinics, huge population base and rising medical insurance services by the Japan government. Moreover, China and Australia hold the significant market share due to the well-supported reimbursement facilities and well-regulated IVD devices, which comes under the regulation of medical devices. However, India registers highest CAGR i.e. 7.1% during the forecast period.
Product launch was the key strategy adopted by market payers, owing to the dynamic nature of the market in terms of technology advancement. The leading companies profiled in this report are, Danaher Corporation, Vela Diagnostics, Siemens AG, Affymetrix, Alere Inc., BioMerieux, Roche Diagnostics, Bio-Rad Laboratories, Becton, Dickinson And Company, Abbott Laboratories Inc., Arkray Inc., Sysmex Corporation, Johnson & Johnson, Siemens Healthcare and Trans Asia BioMedicals Ltd.
KEY BENEFITS FOR STAKEHOLDERS:
APAC IVD MARKET KEY SEGMENTS:
By Product type
Table of Contents
CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Reason for doing the study
1.3 Key take away
1.4 Key market segments
1.5 Research methodology
1.5.1 Secondary Research
1.5.2 Primary Research
1.5.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.3 Key Intelligence
3.3.1 Top impacting factors
3.3.2 Top investment pockets
3.3.3 Top winning strategies
3.4 Governance act and remuneration
3.4.1 Regulations in China
3.4.2 Regulations in India
3.4.3 Regulations in Japan and Australia
3.5 Strategic management insights
3.5.1 Value chain analysis
3.5.1.1 Primary Activity
3.5.1.2 Supportive Activity
3.6 Top player positioning
3.6.1 Porter five forces analysis
3.6.1.1 Brand loyalty leads to moderate bargaining power of supplier
3.6.1.2 Varying product differentiation would lead to moderate bargaining power of buyers
3.6.1.3 Low threat from new entrants due to high entry barriers
3.6.1.4 Less intersegment substitution leads to lower threat Of substitute
3.6.1.5 Moderate competitive rivalry
3.7 Research & analysis
3.7.1 Clinical trials of research studies conducted for IVD market
3.8 Significant progressions in IVD technologies
3.8.1 Total laboratory automation (TLA)
3.8.2 Evolving markets in digital pathology
3.8.3 Omics and genetics tests in IVD
3.8.4 Point-of-care testing
3.8.5 Emerging technologies diagnostics and influence on IVD
3.9 Market dynamics
3.9.1 Drivers
3.9.1.1 Increasing incidences of diseases
3.9.1.2 Technological advancements
3.9.1.3 Focus on prevention and diagnosis
3.9.1.4 Increasing healthcare expenditure
3.9.1.5 Upsurge of companion diagnostics
3.9.2 Restraints
3.9.2.1 Reimbursement issues
3.9.2.2 Stringent regulatory policies
3.9.2.3 UnAffordability of latest sophisticated tests
3.9.3 Opportunities
3.9.3.1 Potential outsourcing Opportunities in laboratory testing
3.9.3.2 Increasing popularity of personalized medicine
CHAPTER 4 ASIA-PACIFIC IVD MARKET, BY PRODUCT TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Reagents
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 Instruments
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.4 Software and services
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
CHAPTER 5 ASIA PACIFIC IVD MARKET, BY TECHNIQUES
5.1 Introduction
5.1.1 Market size and forecast
5.2 Immunodiagnostic
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
5.3 Blood testing
5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast
5.3.4 Key market trends
5.4 Molecular diagnostics
5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast
5.5 Tissue diagnostics
5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast
5.6 Clinical chemistry
5.6.1 Key market trends
5.6.2 Key growth factors and opportunities
5.6.3 Market size and forecast
5.7 Other IVD techniques
5.7.1 Key market trends
5.7.2 Key growth factors and opportunities
5.7.3 Market size and forecast
CHAPTER 6 ASIA PACIFIC IVD MARKET, BY INDICATION
6.1 Introduction
6.1.1 Market size and forecast
6.2 Infectious diseases
6.2.1 Market size and forecast
6.3 Cancer
6.3.1 Market size and forecast
6.4 Cardiac diseases
6.4.1 Market size and forecast
6.5 Immune system disorder
6.5.1 Market size and forecast
6.6 Nephrological diseases
6.6.1 Market size and forecast
6.7 Gastrointestinal disorders
6.7.1 Market size and forecast
6.8 Other indications
6.8.1 Market size and forecast
CHAPTER 7 ASIA PACIFIC IVD MARKET, BY END USERS
7.1 Overview
7.1.1 Market size and forecast
7.1 Stand-alone laboratory
7.1.1 Market size and forecast
7.2 Hospitals
7.2.1 Market size and forecast
7.3 Academics and medical schools
7.3.1 Market size and forecast
7.4 Point of care
7.4.1 Market size and forecast
7.5 Other end users
7.5.1 Market size and forecast
CHAPTER 8 ASIA PACIFIC IVD MARKET, BY COUNTRIES
8.1 Overview
8.1.1 Market size and forecast
8.2 India
8.2.1 Key market trends
8.2.2 Key growth factors and opportunities
8.2.3 Market size and forecast
8.3 China
8.3.1 Competitive analysis
8.3.2 Key growth factors and opportunities
8.3.3Market size and forecast
8.4 Japan
8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size and forecast
8.5 Australia
8.5.1 Key market trends
8.5.2 Key growth factors and opportunities
8.5.3 Market size and forecast
8.6 Others
8.6.1 Key market trends
8.6.2 Key growth factors and opportunities
8.6.3 Market size and forecast
CHAPTER 9 COMPANY PROFILES
9.1 Affymetrix Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Financial performance of Affymetrix Inc.
9.1.4 Key strategies and development
9.1.5 SWOT analysis of Affymetrix
9.2 Alere Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Financial performance of Alere Inc.
9.2.4 Business performance
9.2.5 Key Strategies and developments
9.2.6 SWOT analysis of Alere
9.3 Biomerieux
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Financial performance of BioMerieux
9.3.4 Key Strategies and developments
9.3.5 SWOT analysis of BioMerieux
9.4 F. Hoffmann-La Roche AG
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Financial performance of Roche
9.4.4 Key Strategies and developments
9.4.5 SWOT analysis of Roche Diagnostics
9.5 Becton, Dickinson and Company
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Financial Performance
9.5.4 Key Strategies and development
9.5.5 SWOT analysis
9.6 Bio-Rad Laboratories, Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3Financial Performance
9.6.4Key Strategies and developments
9.6.5SWOT analysis of
9.7 Abbott Laboratories Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Financial Performance
9.7.4 Key Strategies and developments
9.7.5 SWOT analysis
9.8 Transasia Bio-Medicals Ltd.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Key strategies and development
9.8.4 SWOT analysis
9.9 Arkray, Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Key Strategies and development
9.9.4 SWOT analysis
9.10 Sysmex Corporation
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Business performance
9.10.4 Key strategies and developments
9.10.5 SWOT analysis
9.11 Johnson & Johnson
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Business Performance
9.11.4 Key strategies and development
9.11.5 SWOT analysis
9.12 Siemens AG
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Business performance
9.12.4 Key strategies and development
9.12.5 SWOT analysis
9.13 Danaher Corporation
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Business performance
9.13.4 Key strategies and development
9.13.5 SWOT analysis
9.14 Vela Diagnostics
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Key Strategies and development
9.14.4 SWOT analysis
List of Figures
FIG. 1 TOP INVESTMENT POCKETS- 2015-2022
FIG. 2 KEY MARKET STRATEGIES IN IVD MARKET
FIG. 3 TOP WINNING STRATEGIES
FIG. 4 VALUE CHAIN ANALYSIS FOR IVD MARKET
FIG. 5 TOP PLAYER POSITIONING: ASIA PACIFIC IVD MARKET, 2015
FIG. 6 PORTER`S FIVE FORCES MODEL OF ASIA PACIFIC IVD MARKET
FIG. 7 ASIA PACIFIC KEY FACTS ON HIV IN 2013
FIG. 8 AFFYMETRIX INC. REVENUE, 2011-2014, $MILLION
FIG. 9 AFFYMETRIX REVENUE BY SEGMENTS, 2014 (%)
FIG. 10 AFFYMETRIX REVENUE BY GEOGRAPHY, 2014 (%)
FIG. 11 AFFYMETRIX- SWOT ANALYSIS
FIG. 12 ALERE INC. REVENUE, 2011-2014, $MILLION
FIG. 13 ALERE INC.REVENUE BY SEGMENTS, 2014 (%)
FIG. 14 ALERE INC. REVENUE BY GEOGRAPHY, 2014 (%)
FIG. 15 ALERE INC- SWOT ANALYSIS
FIG. 16 BIOMERIEUX REVENUE, 2011-2014, $MILLION
FIG. 17 BIOMERIEUX REVENUE BY APPLICATION, 2014 (%)
FIG. 18 BIOMERIEUX REVENUE BY GEOGRAPHY, 2014 (%)
FIG. 19 BIOMERIEUX- SWOT ANALYSIS
FIG. 20 ROCHE REVENUE, 2011-2014, $MILLION
FIG. 21 ROCHE REVENUES BY SEGMENT, 2014 (%)
FIG. 22 ROCHE REVENUE BY GEOGRAPHY, 2014 (%)
FIG. 23 ROCHE- SWOT ANALYSIS
FIG. 24 BECTON, DICKINSON: REVENUE, 2011-2014, $MILLION
FIG. 25 BECTON DICKINSON REVENUES BY SEGMENT, 2014 (%)
FIG. 26 BECTON DICKINSON: REVENUE BY GEOGRAPHY, 2014 (%)
FIG. 27 BECTON, DICKINSON: SWOT ANALYSIS
FIG. 28 BIO-RAD REVENUE, 2011-2014, $MILLION
FIG. 29 BIO-RAD: REVENUES BY SEGMENT, 2014 (%)
FIG. 30 BIO-RAD: REVENUES BY GEOGRAPHY, 2013 (%)
FIG. 31 BIO-RAD- SWOT ANALYSIS
FIG. 32 ABBOTT LABORATORIES REVENUE, 2011-2014, $MILLION
FIG. 33 ABBOTT LABORATORIES REVENUES BY SEGMENT, 2013 (%)
FIG. 34 ABBOTT LABORATORIES REVENUES BY GEOGRAPHY, 2013 (%)
FIG. 35 ABBOTT LABORATORIES- SWOT ANALYSIS
FIG. 36 TRANSASIA BIO-MEDICALS- SWOT ANALYSIS
FIG. 37 ARKRAY, INC.- SWOT ANALYSIS
FIG. 38 SYSMEX REVENUES BY SEGMENT, 2014 (%)
FIG. 39 SYSMEX REVENUES BY GEOGRAPHY, 2014 (%)
FIG. 40 SYSMEX- SWOT ANALYSIS
FIG. 41 JOHNSON & JOHNSON REVENUES BY SEGMENT, 2014 (%)
FIG. 42 JOHNSON & JOHNSON REVENUES BY GEOGRAPHY, 2014 (%)
FIG. 43 JOHNSON & JOHNSON- SWOT ANALYSIS
FIG. 44 SIEMENS REVENUES BY SEGMENT, 2014 (%)
FIG. 45 SIEMENS REVENUES BY GEOGRAPHY, 2014 (%)
FIG. 46 SIEMENS- SWOT ANALYSIS
FIG. 47 DANAHER CORPORATION REVENUE BY SEGMENT, 2014 (%)
FIG. 48 DANAHER CORPORATION REVENUE BY GEOGRAPHY, 2014 (%)
FIG. 49 DANAHER CORPORATION- SWOT ANALYSIS
FIG. 50 VELA DIAGNOSTICS- SWOT ANALYSIS
List of Table
TABLE 1 CLINICAL TRIALS - IN VITRO DIAGNOSTIC DEVICES
TABLE 2 INCIDENCES OF DISEASES
TABLE 3 GOVERNMENT HEALTHCARE SPENDING IN ASIA PACIFIC COUNTRIES 2011
TABLE 4 COMPARISON OF ESTIMATED HEALTHCARE EXPENDITURE IN ASIA (1999, 2015, 2030) (US$ MILLION)
TABLE 5 ASIA-PACIFIC IVD MARKET, BY PRODUCT TYPE, 20152022 ($MILLION)
TABLE 6 ASIA-PACIFIC IVD REAGENTS MARKET, BY COUNTRY, 20152022 ($MILLION)
TABLE 7 ASIA-PACIFIC IVD INSTRUMENTS MARKET, BY COUNTRY, 20152022 ($MILLION)
TABLE 8 ASIA PACIFIC IVD SOFTWARE & SERVICES MARKET, BY COUNTRY, 20152022 ($MILLION)
TABLE 9 ASIA-PACIFIC IVD MARKET, BY TECHNIQUES, 2015-2022 ($MILLION)
TABLE 10 ASIA-PACIFIC IMMUNODIAGNOSTICS MARKET, BY COUNRTY, 2015-2022 ($MILLION)
TABLE 11 ASIA-PACIFIC BLOOD TESTING MARKET, BY COUNRTY, 2015-2022 ($MILLION)
TABLE 12 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY COUNRTY, 2015-2022 ($MILLION)
TABLE 13 ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET, BY COUNRTY, 2015-2022 ($MILLION)
TABLE 14 ASIA-PACIFIC CLINICAL CHEMISTRY MARKET, BY COUNRTY, 2015-2021 ($MILLION)
TABLE 15 ASIA-PACIFIC OTHER IVD TECHNIQUES MARKET, BY COUNRTY, 2015-2022 ($MILLION)
TABLE 16 ASIA-PACIFIC IVD MARKET, INDICATION ,2015-2022, ($MILLION)
TABLE 17 ASIA-PACIFIC INFECTIOUS DISEASES MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 18 ASIA-PACIFIC CANCER MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 19 ASIA-PACIFIC CARDIAC DISEASE MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 20 ASIA-PACIFIC IMMUNE SYSTEM DISORDER MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 21 ASIA-PACIFIC NEPHROLOGICAL DISEASES MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 22 ASIA-PACIFIC GASTROINTESTINAL DISEASES MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 23 ASIA-PACIFIC OTHER INDICATIONS MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 24 ASIA-PACIFIC IVD MARKET, BY END USERS, 2015-2022 ($MILLION)
TABLE 25 ASIA-PACIFIC IVD STAND-ALONE LABORATORY MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 26 ASIA-PACIFIC IVD HOSPITALS MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 27 ASIA-PACIFIC IVD ACADEMICS AND MEDICAL SCHOOL MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 28 ASIA-PACIFIC IVD POINT OF CARE MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 29 ASIA-PACIFIC IVD OTHER END USERS MARKET, BY COUNTRY, 2015-2022($MILLION)
TABLE 30 ASIA-PACIFIC IVD MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 31 INDIA IVD MARKET, BY TECHNIQUES, 2015-2022($MILLION)
TABLE 32 REGULATORY SUMMARY FOR IVD DEVICES IN CHINA
TABLE 33 CHINA IVD MARKET, BY TECHNIQUES, 2015-2022($MILLION)
TABLE 34 JAPAN IVD MARKET, BY TECHNIQUES, 2015-2022($MILLION)
TABLE 35 CATEGORIZATION OF IVD DEVICES
TABLE 36 AUSTRALIA IVD MARKET, BY TECHNIQUES, 2015-2022($MILLION)
TABLE 37 OTHER COUNTRIES IVD MARKET, BY TECHNIQUES, 2015-2022($MILLION)
TABLE 38 VELA DIAGNOSTICS COMPANY SNAPSHOT
TABLE 39 COMPANY SNAPSHOT AFFYMETRIX INC.
TABLE 40 COMPANY SNAPSHOT ALERE INC
TABLE 41 BIOMERIEUX COMPANY SNAPSHOT
TABLE 42 COMPANY SNAPSHOT OF ROCHE DIAGNOSTICS
TABLE 43 COMPANY SNAPSHOT OF BECTON, DICKINSON AND COMPANY
TABLE 44 SNAPSHOT OF BIO-RAD LABORATORIES
TABLE 45 SNAPSHOT OF ABBOTT LABORATORIES INC
TABLE 46 TRANSASIA BIOMEDICALS OPERATING BUSINESS SEGMENTS
TABLE 47 COMPANY SNAPSHOT OF ARKRAY INC
TABLE 48 COMPANY SNAPSHOT OF SYSMEX CORPORATION
TABLE 49 JOHNSON & JOHNSON COMPANY SNAPSHOT
TABLE 50 SIEMENS COMPANY SNAPSHOT
TABLE 51 DANAHER CORPORATION COMPANY SNAPSHOT
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : November 2019
$ 3600
Published On : November 2019
$ 3600
Published On : November 2019
$ 3600
$ 3950
Published On : April 2019
$ 3000
